by emma
25. October 2011 13:39
Sanofi has appointed David Meeker as CEO of Genzyme to incorporate its Rare Disease and Multiple Sclerosis franchises.
He will join the company’s Group Management Committee, reporting to Sanofi’s CEO, Christopher Viehbacher.
He said that David’s “medical and business experience will be essential to move Genzyme’s broad portfolio of products forward and deliver much-needed therapies to patients”.
Mr Meeker joined Genzyme in 1994 as medical director to work on the company’s Cystic Fibrosis Gene Therapy programme. He has since held various positions at the company, including President of Global Rare Disease Business, and was promoted to Chief Operating Officer in 2009.
Sanofi is a global healthcare provider, which develops and distributes therapeutic solutions in diabetes care, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
018b0545-f5f4-45bf-9d93-6a3121399289|0|.0
Tags: CEO, Genzyme, Sanofi, appoint, appointment, David Meeker, Rare Disease, multiple sclerosis, MS, company, Group management committee, Christopher Viehbacher, medical, business, experience, portfolio of products, therapies, patients, medical director, cystic fibrosis, CS, healthcare provider, therapeutic solutions, diabetes care, human vaccines, innovative drugs, rare diseases, consumer healthcare, Emerging Markets, animal health, industry, sector
Appointments
Subscribe